MRK · NYSE · STOCK
Merck & Co. (MRK) Stock Analysis
$152.56
52W $77.58 – $154.49
62/100
$376.77B
121.1
0.21
Is MRK Bullish or Bearish?
Bullish.
Innellis AI committee rates Merck & Co. (MRK) Buy with a composite score of 62/100
, based on 5 analysts with 80% agreement.
Last updated August 23, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +13.01 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -6.99 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — 5 consecutive earnings beats -- consistent execution. Risk Analyst remains cautious — bollinger bandwidth of 23.4% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- RSI at 83 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
- Weekly RSI at 81 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 23.4% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 23, 2026
Overall Committee Score
62/100
Agreement
80%
Analysts
5
Conviction
Contested
Sector Rank
Top 25%
of 192 Healthcare peers
Growth Analyst
bullish
82
/ 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ 5 consecutive earnings beats -- consistent execution
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− RSI at 83 is in overbought territory
Risk Analyst
bearish
35
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Bollinger bandwidth of 23.4% signals elevated volatility
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
66
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.27 across 140 articles, 14d)
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 3069.37)
Investment Thesis Evolution
Committee score strengthened from 54.2 to 62.0.
- Recommendation changed from Watch to Buy.
- Committee agreement increased sharply from 50% to 80%.
- Bullish support removed: 2 signal(s) disappeared.
- Bearish pressure eased: 3 signal(s) disappeared.
- Analyst(s) changed stance: Growth Analyst.
- Analyst(s) abstained: Value Analyst.
Analyst-level changes:
- Growth Analyst: stance neutral->bullish; score 56->82 (+26).
- Value Analyst abstained (was neutral at 42).
Comparing 2026-08-22 to 2026-08-23 (1 day apart).
Technical Analysis
RSI (14)
82.8
Overbought
MACD Histogram
2.109
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Bollinger %B
1.08
Above Upper Band
Price vs Moving Averages
EMA 9
$142.13
Above
EMA 21
$135.97
Above
EMA 50
$129.66
Above
EMA 200
$116.11
Above
Fundamental Analysis
Valuation
33
Growth
65
Profitability
81
Financial Health
52
Cash Flow
70
Valuation
P/E Ratio
121.1×
P/B Ratio
8.99×
PEG Ratio
-1.50
Dividend Yield
2.20%
52W High
$154.49
52W Low
$77.58
Quality & Growth
ROE
3469.9%
ROA
1333.7%
Gross Margin
7537.6%
Operating Margin
1665.1%
Revenue Growth YoY
—
Debt / Equity
1.29
AI Fundamental Assessment
P/E ratio of 121.1 (rich relative to a 15-40x range); Price-to-book of 9.0x; PEG ratio of -1.5 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 34.7%; Return on assets of 13.3%; Net margin of 4.8%; Gross margin of 75.4%; Current ratio of 1.32 (tight short-term liquidity); Debt-to-equity of 1.29; Free cash flow per share is positive (6.50); Most recent quarter beat estimates by 52.3%; 5 consecutive earnings beats; EPS growth accelerating (-161.2% -> +89.8% QoQ); Average YoY EPS growth of -105.9%; Analyst estimates falling over recent quarters
Get the Full MRK Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →